Please assess the completion status of the following clinical trial:

Trial Title: Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-60 years, male or female~* DSM-IV criteria for schizophrenia.~* Ability and willingness to sign informed consent for participation in the study~* SANS (Scale of Negative Symptoms of Schizophrenia ) \> 30 points~* Fixed antipsychotic dosages at least 3 months~* Steady mental state of patients at least 3 months~Exclusion Criteria:~* Current substance use disorder except nicotine dependence~* Regular use of NSAID (non-steroidal anti-inflammatory drugs)~* Cancer history~* Untreated or severe hypertension~* Poorly controlled diabetes mellitus Type I or Type II~* Chronic liver \& gallbladder diseases~* Recent GERD (Gastroesophageal Reflux Disorder)~* Neurological disorders: epilepsy, stroke~* Hamilton Depression Scale Hamilton Depression Rating Scale (HAM-D-17 item) \> 24 points~* Patients with a known hypersensitivity to curcumin~* Pregnant women or a woman who intends to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- curcumin (Type: ACTIVE_COMPARATOR): curcumin 3 g/day for 6 months
- placebo (Type: PLACEBO_COMPARATOR): curcumin 3 g/day for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).